• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Verve Therapeutics Inc.

    4/25/25 7:45:44 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERV alert in real time by email
    DEFA14A 1 d933474ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

     

    Verve Therapeutics, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    P.O. BOX 8016, CARY, NC 27512-9903 Your vote Verve Therapeutics, Inc. Annual Meeting of Stockholders Thursday, June 5, 2025 9:00 AM, Eastern Time Annual Meeting to be held live via the Internet. You must register to attend the meeting online and/or participate prior to the deadline of June 4, 2025 at 5:00 pm ET. Please visit www.proxydocs.com/VERV for more details For a convenient way to view proxy materials, VOTE, and obtain directions to register for and attend the meeting, go to www.proxydocs.com/VERV To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 26, 2025. Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 5, 2025 For Stockholders of record as of April 11, 2025 Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report To order paper materials, use one of the following methods. Internet: www.investorelections.com/VERV Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number SEE REVERSE FOR FULL AGENDA Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or itsaffiliates.All


    LOGO

    Body Text;Verve Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH OF THE NOMINEES IN PROPOSAL 1, AND FOR PROPOSALS 2 AND 3. Election of three Class I directors to our board of directors, each to serve until the 2028 annual meeting of stockholders. Lonnel Coats Jodie Morrison Krishna Yeshwant, M.D. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 Approval, on an advisory basis, of the compensation paid to our named executive officers. NOTE: To transact other business properly brought before the Annual Meeting or any adjournment or postponement thereof.

    Get the next $VERV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERV

    DatePrice TargetRatingAnalyst
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    4/8/2024$15.00Buy
    H.C. Wainwright
    4/13/2023$29.00Buy
    Canaccord Genuity
    2/1/2023$21.00Neutral
    Cantor Fitzgerald
    12/15/2022$13.00Sell
    Goldman
    10/6/2022$48.00Neutral
    Credit Suisse
    8/25/2022$32.00 → $56.00Hold → Buy
    Stifel
    6/17/2022$48.00Outperform
    BMO Capital Markets
    More analyst ratings

    $VERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Maclean Michael F

    4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

    7/28/25 5:15:34 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Yeshwant Krishna

    4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

    7/28/25 5:15:32 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Administrative Officer Nickerson Joan closing all direct ownership in the company (SEC Form 4)

    4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

    7/28/25 5:15:26 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

    INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (NASDAQ:VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. "We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines

    7/25/25 8:49:00 AM ET
    $LLY
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly and Verve announce expiration of Verve tender offer

    INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Verve Therapeutics, Inc. (NASDAQ:VERV) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common stock in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone (the "Offer"), exp

    7/24/25 8:00:00 AM ET
    $LLY
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

    Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovasc

    6/17/25 6:45:00 AM ET
    $LLY
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Verve Therapeutics upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded Verve Therapeutics from Neutral to Overweight

    4/15/25 8:57:58 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Verve Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $15.00

    4/8/24 8:03:41 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Verve Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $29.00

    4/13/23 7:37:44 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERV
    SEC Filings

    View All

    SEC Form 15-12G filed by Verve Therapeutics Inc.

    15-12G - Verve Therapeutics, Inc. (0001840574) (Filer)

    8/4/25 8:00:30 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Verve Therapeutics Inc.

    EFFECT - Verve Therapeutics, Inc. (0001840574) (Filer)

    7/29/25 12:15:04 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Verve Therapeutics Inc.

    SCHEDULE 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

    7/28/25 5:21:44 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ashe Andrew D. bought $475,760 worth of shares (76,000 units at $6.26), increasing direct ownership by 29% to 342,509 units (SEC Form 4)

    4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

    5/15/24 5:30:07 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yeshwant Krishna bought $18,000,000 worth of shares (1,800,000 units at $10.00) (SEC Form 4)

    4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

    12/5/23 4:30:09 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERV
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

    BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

    9/18/23 6:30:00 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

    CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

    6/13/22 6:30:00 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERV
    Financials

    Live finance-specific insights

    View All

    Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

    Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

    4/14/25 7:00:00 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

    LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing hear

    11/12/23 3:30:00 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

    SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/12/24 5:52:40 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

    SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/4/24 1:52:43 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care